Common (≥1/100 to < 1/10) undesirable effects were observed with equal incidence in control and InductOs treatment groups, with the following four exceptions which were observed significantly more frequently in the InductOs treatment group than in the control group: • blood amylase increased (without overt signs of pancreatitis in InductOs treated patients), • tachycardia, • hypomagnesemia, • headache.
Sagedaste (> 1/ 100 kuni < 1/ 10) kõrvaltoimete esinemissagedus oli kontrollrühmas ja InductOs- rühmas sarnane nelja järgmise erandiga, mida täheldati InductOs- rühmas kontrollrühma patsientidega võrreldes märkimisväärselt sagedamini: • vere amülaasitaseme suurenemine (InductOs- rühma patsientidel, ilma et sellega oleks kaasnenud pankreatiidi kliinilist sümptomaatikat), • tahhükardia, • hüpomagneseemia, • peavalu.